Delving into the Latest Updates on Nicardipine Hydrochloride with Synapse

This is a single-center double blind, placebo controlled study of patients undergoing a cardiac catheterization where the need for a percutaneous coronary intervention (PCI) is anticipated or will be determined during the early diagnostic phase. The study will assess the use of intracoronary nicardipine vs. sterile saline injection in reducing the index measurement of microcirculatory resistance (IMR). Fifty consecutive patients presenting to the Thomas Jefferson University (TJUH) Cardiac Catheterization lab will be randomized in a 1:1 fashion to receive either intracoronary nicardipine or sterile saline injection prior to PCI. IMR values will be assessed pre and post procedure. Data on clinical outcomes and adverse events will be collected by phone at 30 days and 1 year following the procedure.

Start Date01 Dec 2025

Sponsor / Collaborator

Thomas Jefferson University

NCT06093893 / Not yet recruitingPhase 4IIT

A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events.
The specific objectives of this study are to compare:
1. Dexmedetomidine, Nicardipine, and Labetalol's effect on the quality of the surgical field. (Primary Outcome)
2. Dexmedetomidine, Nicardipine, and Labetalol's effect on estimated blood loss.
3. Dexmedetomidine, Nicardipine, and Labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate.
4. Dexmedetomidine, Nicardipine, and Labetalol's effect on operation time.
5. Dexmedetomidine, Nicardipine, and Labetalol's effect on adverse events.
The investigators will evaluate healthy adult male and female patients who require jaw surgery at Boston Medical Center. The anticipated 90 participants will be randomized into three groups: ) A Labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) A Nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) A Dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine.
The time it will take for each individual participant ranges from 1-3 months. This time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.

Start Date01 May 2024

Sponsor / Collaborator

Boston Medical Center

NCT06329635 / Not yet recruitingNot ApplicableIIT

Trial of Treatment of Vasospasm Associated With Aneurysmal Subarachnoid Hemorrhage With Intrathecal Injection of Nicardipine: a Multi-center, Prospective, Double-blinded, Randomized Controlled Trial

To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.

Start Date01 Apr 2024

Sponsor / Collaborator

The Affiliated Hospital of Guizhou Medical University

100 Clinical Results associated with Nicardipine Hydrochloride

Login to view more data

100 Translational Medicine associated with Nicardipine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Nicardipine Hydrochloride

Login to view more data

9,237

Literatures (Medical) associated with Nicardipine Hydrochloride

31 Dec 2024·Hypertension in Pregnancy

Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review

Review

Author: Wang, Ting ; Jiang, Ruoan ; Yao, Yingsha ; Xu, Ting ; Li, Na

BACKGROUNDPreeclampsia (PE) is a pregnancy disorder that represents a major cause of maternal and perinatal morbidity and mortality.METHODSThis network meta-analysis was registered with PROSPERO. We searched the PubMed, ClinicalTrials.gov. and Embase databases for studies published from inception to the 31^st of March 2023. RevMan5.3 software provided by the Cochrane Collaboration was used for direct meta-analysis (DMA) statistical analysis. Funnel maps, network meta-analysis (NMA), the surface under the cumulative ranking curve (SUCRA) to rank the different interventions and publication bias were generated by STATA 17.0 software.RESULTSWe included eight randomized controlled trials (RCTs) involving a total of 1192 women with PE; two studies were of high quality and six were of moderate quality. Eight interventions were addressed in the NMA. In the DMA, we found that blood pressure in the Ketanserin group were significantly higher than those in the Nicardipine group. NMA showed that blood pressure in the Dihydralazine group was significantly higher than that in the Methyldopa, Labetalol, Nicardipine and Diltiazem groups. And the blood pressure in the Labetalol group was significantly lower than that in the Nicardipine group. SUCRA values showed that Diltiazem was more effective in lowering blood pressure than other drugs looked at in this study.CONCLUSIONAccording to the eight RCTs included in this study, Diltiazem was the most effective in reducing blood pressure in PE patients; Labetalol and Nicardipine also had good effects. Diltiazem is preferred for the treatment of patients with severe PE and high blood pressure.

01 Jul 2024·Talanta

Direct investigations of the effects of nicardipine on calcium channels of astrocytes by Atomic Force Microscopy

Article

Author: Zhao, Weidong ; Zou, Yulan ; Zhong, Haijian ; Meng, Yu ; Guo, Zeling ; Liao, Wenchao ; Li, Xinyu ; Feng, Rongrong ; Peng, Qianwei

Calcium channel blockers (CCB) of astrocytes can blockade the calcium ions entry through the voltage gated calcium channels (VGCC), and is widely used in the diseases related with VGCC of astrocytes. But many aspects of the interaction mechanisms between the CCB and VGCC of astrocytes still remain unclear due to the limited resolution of the approaches. Herein the effects of the nicardipine (a type of CCB) on VGCC of astrocytes were investigated at very high spatial, force and electrical resolution by multiple modes of Atomic Force Microscopy (AFM) directly. The results reveal that after the addition of nicardipine, the recognition signals of VGCC disappeared; the specific unbinding forces vanished; the conductivity of the astrocytes decreased (the current decreased about 2.9 pA and the capacitance was doubled); the surface potential of the astrocytes reduced about 14.2 mV. The results of electrical properties investigations are consistent with the simulation experiments. The relations between these biophysical and biochemical properties of VGCC have been discussed. All these demonstrate that the interactions between nicardipine and VGCC have been studied at nanometer spatial resolution, at picoNewton force resolution and very high electrical signal resolution (pA in current, pF in capacitance and 0.1 mV in surface potential) level. The approaches are considered to be high resolution and high sensitivity, and will be helpful and useful in the further investigations of the effects of other types of CCB on ion channels, and will also be helpful in the investigations of mechanisms and therapy of ion channelopathies.

01 Jun 2024·Research in Veterinary Science

Nicardipine constant rate infusion alleviates the cardiovascular effects of dexmedetomidine infusions without affecting the minimal alveolar concentration in sevoflurane-anesthetized dogs

Article

Author: Hikasa, Yoshiaki ; Murahata, Yusuke ; Imagawa, Tomohiro ; Akashi, Natsuki ; Kanazawa, Aomi ; Tsuno, Sayaka

Two randomized crossover trials evaluated the effects of nicardipine constant rate infusion (CRI) on 1) the anesthetic potency of sevoflurane and 2) the ability to attenuate dexmedetomidine-induced cardiovascular depression in anesthetized dogs. First, six healthy Beagle dogs weighing 11.7 ± 0.9 kg were allocated to one of three treatments that administered a CRI of carrier (saline) or dexmedetomidine 0.5 or 3.0 μg/kg/h following a loading dose. The minimum alveolar concentration (MAC) of sevoflurane was determined utilizing electric stimuli before and after the loading dose of nicardipine (20 μg/kg intravenously for 10 min), followed by CRI at 40 μg/kg/h with 60 min of equilibration. Subsequently, cardiovascular and blood gas variables were evaluated in another trial under sevoflurane anesthesia at the individual 1.5 MAC. After baseline measurements, the dogs were assigned to two treatments (dexmedetomidine CRI at 0.5 or 3.0 μg/kg/h following a loading dose) with sevoflurane doses adjusted to 1.5 times of MAC equivalent, and the measurements were repeated every 15 min for 120 min. After 60 min, nicardipine CRI at 40 μg/kg/h with a loading dose was added to the dexmedetomidine CRI. Dexmedetomidine infusions significantly decreased the sevoflurane MAC but nicardipine did not significantly alter the MAC either with or without dexmedetomidine CRI in dogs. Dexmedetomidine dose-dependently decreased the cardiac index and increased the systemic vascular resistance index; these effects were fully counteracted by concomitant nicardipine CRI. Nicardipine CRI can be useful for controlling the cardiovascular depression elicited by dexmedetomidine in anesthetized dogs without affecting the anesthetic potency of sevoflurane.

1

News (Medical) associated with Nicardipine Hydrochloride

25 Sep 2023

·www.prnewswire.com

Senores Pharmaceuticals, Inc. announces the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg in the U.S. market

ATLANTA, Sept. 25, 2023 /PRNewswire/ -- Senores Pharmaceuticals, Inc. announced the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg, a bioequivalent and therapeutically equivalent to Cardene Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. in the U.S. market. The product will be marketed by Burel Pharmaceuticals, LLC. Nicardipine Hydrochloride Capsules USP are indicated for the management of patients with chronic stable angina (effort-associated angina) and for the treatment of hypertension. Continue Reading Senores Pharmaceuticals, Inc. announces the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg in the U.S. market (PRNewsfoto/Senores Pharmaceuticals Inc.) Senores Pharmaceuticals, Inc. has been granted a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg. Therefore, with this approval, Senores is eligible for 180 days of CGT exclusivity upon commercial marketing. "We are pleased to announce the commercial launch of Nicardipine Hydrochloride Capsules in the U.S. through our marketing partner," stated Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. "At Senores, the pursuit for better healthcare drives our actions. With this launch and an ever-expanding product portfolio, we envision a healthier tomorrow," stated S Shah, Managing Director, Senores Pharmaceuticals Limited. About Senores Pharmaceuticals, Inc. Senores Pharmaceuticals, Inc., based in Georgia, USA is one of the fastest-growing pharmaceutical companies in the U.S. market. The company has more than 20 products commercially launched or filed with the USFDA. For more information about Senores Pharmaceuticals, Inc., please visit Senores Pharmaceuticals, Inc. Georgia USA Photo: SOURCE Senores Pharmaceuticals Inc.

Drug ApprovalBreakthrough Therapy

100 Deals associated with Nicardipine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00617	Nicardipine Hydrochloride	C08CA04	DB00622

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Angina Pectoris	CN	Jiangsu Desano Pharmaceutical Co. Ltd.	01 Jan 1988
Hypertension	CN	Jiangsu Desano Pharmaceutical Co. Ltd.	01 Jan 1988
Essential Hypertension	JP	LTL Pharma Co., Ltd.	01 May 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Subarachnoid Hemorrhage	Phase 1	DE	BIT Pharma GmbH	05 Apr 2020
Subarachnoid Hemorrhage	Phase 1	AT	BIT Pharma GmbH	05 Apr 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P3.101 (AAN2015)	Not Applicable	Cerebral Hemorrhage	35	Nicardipine	(ssngsloiiu) = nkdqguuove dgywjacyxv (vplrmwuqzy )	Positive	06 Apr 2015
				Nicardipine	(ssngsloiiu) = sabyjnnwjo dgywjacyxv (vplrmwuqzy )
ISC2015	Not Applicable	Ischemic stroke \| Hypertension	-	Nicardipine	(quksqrxxin) = udrcbbzvvi dxmckgpjca (gycinvvqrm ) View more	-	01 Feb 2015
				Labetalol	(quksqrxxin) = rwcdatliht dxmckgpjca (gycinvvqrm ) View more
ARVO2017	Not Applicable	Vascular Diseases	6	Nicardipine	(cnxehbuovz) = vzcdmgigty ijqmtzdqkl (jlbmybzbmv )	Positive	07 May 2017
				Verapamil	(cnxehbuovz) = yuthaoahbj ijqmtzdqkl (jlbmybzbmv )
ESC2018	Not Applicable	-	-	Nicardipine	tlmporhewp(ejyjwswimq) = zcpyugbbdm ryubbrhhwj (mjxjzeizlq ) View more	-	20 Apr 2018
ISC2023	Not Applicable	Cerebral Hemorrhage	370	Intravenous Nicardipine	dupkfxcjva(uiefuihvhr) = rzeoneuqpk xcitsjpqoh (gqplvisthk )	-	01 Feb 2023
ISC2020	Not Applicable	Subarachnoid Hemorrhage	-	IT Nicardipine	poprhjwfpg(qzbbybnrmw) = oepbabcpjj zzxqeladzx (bpjoycwkfa )	-	01 Feb 2020
ISC2018	Not Applicable	Cerebral Hemorrhage	59	i.v. Nicardipine only	(cuakenormt) = bradycardia occurred in three patients of combination treatment group etzkxofxih (eepmolqdqv )	-	22 Jan 2018
				Bisoprolol transdermal patch and i.v. Nicardipine
AAIC2016	Not Applicable	Cognitive Dysfunction	133	Cholinesterase inhibitors	(qenryelmqi) = cholinesterase inhibitors have some cognitive benefit in vascular and mixed dementia, without clear benefit for activities of daily living affypoyvyp (ttgbduqyqs )	-	01 Jul 2016
				Propentofylline
P5.3-059 (AAN2019)	Not Applicable	-	-	Nicardipine	glhuumbtbh(oirvxxopcc) = glfndqglpe fwvnjygaqp (fvnkzemkob )	-	09 Apr 2019
				Oral antihypertensive	glhuumbtbh(oirvxxopcc) = ghfmkpwkds fwvnjygaqp (fvnkzemkob )
P3.3-064 (AAN2019)	Not Applicable	-	205	Labetalol	kqfyrfhtby(rmskugxuvb) = wwduoghlyt jdcuqchjmn (plqmcymcok ) View more	-	09 Apr 2019
				Nicardipine	kqfyrfhtby(rmskugxuvb) = sjnlatvdcj jdcuqchjmn (plqmcymcok ) View more